Skip Navigation Links
SEARCH  



 
Bookmark and Share
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
This marks the third FDA approval for BRUKINSA and first approval in marginal zone lymphoma Twenty percent of patients achieved complete remission with single-agent BRUKINSA BRUKINSA was generally well-tolerated, consistent with its known safety pro...

Full "IntellAsia: Resources" article




Disclaimer | Terms Of Use And Privacy Statement


© Metals News. All rights reserved.